Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Liver Cancer

Liver Cancer

10 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Liver Cancer

175 trials tracked for Liver Cancer: 18 in phase 3 or 4 and 10 with published results. The most-cited published study has 267 citations.

175Trials tracked
18Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 3 Phase 3 15 Phase 2 108 Phase 1 12 Other / NA 37
  1. Phase 3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed · 267 cited
  2. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 133 cited
  3. Phase 3 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed · 115 cited
  4. Phase 3 Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Completed · 100 cited
  5. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 94 cited
  6. Phase 3 Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas Completed · 86 cited
Show 44 more trials
  1. Phase 3 Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection Completed · 81 cited
  2. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Completed · 56 cited
  3. Phase 3 Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer Completed · 21 cited
  4. Phase 3 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival Completed · 8 cited
  5. Phase 4 SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA Completed
  6. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  7. Phase 3 SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization Completed
  8. Phase 3 SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization Completed
  9. Phase 3 Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC Completed
  10. Phase 3 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer Completed
  11. Phase 3 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma Completed
  12. Phase 3 Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer Completed
  13. Phase 2 Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed
  14. Phase 2 A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Completed
  15. Phase 2 Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Completed
  16. Phase 2 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Completed
  17. Phase 2 Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Completed
  18. Phase 2 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed
  19. Phase 2 Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma Completed
  20. Phase 2 Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets Completed
  21. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  22. Phase 2 Sorafenib + mFOLFOX for Hepatocellular Carcinoma Completed
  23. Phase 2 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed
  24. Phase 2 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Completed
  25. Phase 2 Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Completed
  26. Phase 2 Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Completed
  27. Phase 2 Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Completed
  28. Phase 2 Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers Completed
  29. Phase 2 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed
  30. Phase 2 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Completed
  31. Phase 2 Survivorship Promotion In Reducing IGF-1 Trial Completed
  32. Phase 2 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver Completed
  33. Phase 2 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer Completed
  34. Phase 2 Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy Completed
  35. Phase 2 Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer Completed
  36. Phase 2 Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Completed
  37. Phase 2 Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery Completed
  38. Phase 2 Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed
  39. Phase 2 IMC-A12 in Treating Patients With Advanced Liver Cancer Completed
  40. Phase 2 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed
  41. Phase 2 PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection Completed
  42. Phase 2 Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer Completed
  43. Phase 2 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed
  44. Phase 2 A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed

Showing the 50 most-cited and recently-updated of 175 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Liver Cancer: what the trials found

Sorafenib has demonstrated a statistically significant improvement in progression-free survival (p=0.0001) and time to progression (p=0.034) compared to the control group 9. However, its impact on overall survival did not reach statistical significance (p=0.0554) 9.

Imaging and diagnostic modalities show varying results. SonoVue-enhanced ultrasound demonstrated significant improvements in sensitivity (p=<0.0001) and accuracy (p=<0.0001) 17, while a separate study on SonoVue-enhanced ultrasound showed significant improvements in specificity (p=<0.0001) and accuracy (p=<0.0001) 18.

Other interventions include NIK-333 (peretinoin), which showed no significant difference in recurrence-free survival (p=0.351), disease-free survival (p=0.222), or time to recurrence (p=0.279) 16. Doxorubicin Hydrochloride did not show significant differences in overall survival (p=0.24) or progression-free survival (p=0.98) 8. Cisplatin also showed no significant difference in overall survival (p=0.41) 12.

Sunitinib malate was associated with a 5.88% occurrence of severe bleeding and/or liver failure in one arm compared to 2.78% in the other 13. Stereotactic Body Radiotherapy showed no significant difference in progression-free survival (p=0.36) or the rate of new metastases (p=0.91) 14.

Recent results — preliminary, needs further review

  • * Pembrolizumab was evaluated in a Phase 1 trial 1. * CBCT Imaging was evaluated for image quality (Contrast to Noise Ratio) 2. * SHR-1210 was evaluated in a Phase 2 trial 21. * Acupuncture Therapy was evaluated for the management of chemotherapy-induced peripheral neuropathy (CIPN) 22.

For the clinician treating this condition

  • Sorafenib is associated with statistically significant improvements in progression-free survival and time to progression 9.
  • SonoVue-enhanced ultrasound provides significant improvements in diagnostic accuracy and sensitivity/specificity [17, 18].
  • Several systemic therapies, including Doxorubicin, Cisplatin, and NIK-333, did not show statistically significant improvements in primary survival endpoints in the reported trials [8, 12, 16].

AI synthesis of 12 cited trials, updated Oct 1, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Lysine crotonylation drives tumor progression and may potentiate immunotherapy response in various solid tumors
Dermatology Sys. Review
Lysine crotonylation drives tumor progression and may potentiate immunotherapy response in various solid tumors New Biological Markers May Help Doctors Target Growth in Several Cancer Types
This narrative review explores the role of lysine crotonylation (Kcr) in cancer biology across multiple solid tumor types. The authors concl…
Scientists are looking at how a specific protein change called crotonylation helps cancer grow and may help improve immunotherapy results.
Frontiers Oct 24, 2026
Liver cancer patients experience 74% prevalence of financial toxicity with moderate severity scores
Urology Meta-analysis
Liver cancer patients experience 74% prevalence of financial toxicity with moderate severity scores Most liver cancer patients face high costs during their treatment
This meta-analysis of 39 studies indicates a 74% prevalence of financial toxicity among patients with liver cancer. While prevalence is high…
Nearly three-quarters of liver cancer patients report financial toxicity, highlighting the heavy economic burden of managing this serious il…
Frontiers Oct 16, 2026
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer
Oncology Meta-analysis
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer Comparing the risks of liver cancer from hepatitis versus lung cancer from smoking
This meta-analysis of 86,097,714 participants analyzed the relative risks of liver cancer from various exposures compared to lung cancer fro…
New data shows that certain hepatitis viruses pose a much higher risk for liver cancer than smoking does for lung cancer.
Sep 2, 2026
Fecal microbiota transplantation may modulate tumor microenvironment and enhance immunotherapy responses in several cancers
Oncology Sys. Review
Fecal microbiota transplantation may modulate tumor microenvironment and enhance immunotherapy responses in several cancers Fecal Microbiota Transplantation Shows Potential for Several Cancer Treatments
This systematic review explores the role of fecal microbiota transplantation (FMT) in treating colorectal cancer, liver cancer, and melanoma…
Fecal microbiota transplantation may help manage side effects and improve how the body responds to cancer treatments like chemotherapy and i…
Frontiers Aug 2, 2026
PFOA exposure linked to modest kidney and breast cancer risk in meta-analysis
Oncology Meta-analysis
PFOA exposure linked to modest kidney and breast cancer risk in meta-analysis PFOA exposure tied to higher kidney and breast cancer risk
This meta-analysis of 34 datasets found that perfluorooctanoic acid (PFOA) exposure is associated with a modest increase in kidney cancer ri…
A new analysis links PFOA, a common chemical, to a modest rise in kidney and breast cancer risk. Liver and thyroid cancers showed no clear l…
Aug 2, 2026
Hepatic vein occlusion with portal vein embolization yields 24.5% greater future liver remnant increase
Gastroenterology Meta-analysis
Hepatic vein occlusion with portal vein embolization yields 24.5% greater future liver remnant increase New surgical techniques show larger liver growth before surgery
This meta-analysis of 5,891 patients undergoing 2-stage hepatectomy found that hepatic vein occlusion combined with portal vein embolization…
Combining specific blood vessel techniques can significantly increase the size of a patient's remaining liver before major cancer surgery.
Jul 1, 2026
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Oncology Meta-analysis
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
Frontiers Jun 11, 2026
Narrative review of lung, breast, liver, and kidney cancer evidence
Urology Meta-analysis
Narrative review of lung, breast, liver, and kidney cancer evidence New Cancer Tests Could Spot Tumors Years Earlier Than Before
This narrative review synthesizes published English-language evidence on lung, breast, liver, and kidney cancers. The authors note the scope…
A new wave of cancer biomarker tests can spot lung, breast, liver, and kidney tumors years earlier, opening the door to faster treatment and…
Frontiers May 9, 2026
Review of combination strategies for digestive system tumors including gastric and colorectal cancer
Allergy & Immunology Sys. Review
Review of combination strategies for digestive system tumors including gastric and colorectal cancer Unlocking New Ways to Beat Drug Resistance in Digestive Cancers
This review examines theoretical approaches to enhance efficacy in patients with digestive system tumors, including gastric, colorectal, and…
Researchers are finding better ways to combine treatments so drugs keep working longer.
Frontiers Apr 23, 2026
Laparoscopic hemihepatectomy shows higher costs but better QALYs than open approach in European trial
Gastroenterology RCT
Laparoscopic hemihepatectomy shows higher costs but better QALYs than open approach in European trial Laparoscopic surgery costs more upfront but may offer better value for some liver patients
A phase 3 randomized controlled trial of 332 patients undergoing hemihepatectomy at 16 European centers found laparoscopic surgery had highe…
Laparoscopic liver surgery costs more upfront but delivers better long-term value and quality of life for patients.
Apr 10, 2026

Questions about Liver Cancer

Does laparoscopic surgery for Liver Cancer result in better quality of life?

Laparoscopic liver surgery generally offers a faster recovery and fewer complications than open surgery, which can improve quality of life, though long-term survival is similar.

Full answer →
Are there new combination strategies for treating tumors like Liver Cancer?

Yes, new combination strategies for liver cancer are emerging, including immunotherapy with anti-angiogenic drugs, and surgical techniques like hepatic vein occlusion with portal vein embolization to improve outcomes.

Full answer →